Go or no go? Lecanemab’s destiny approaches
2023 begins with FDA decisions for Eisai’s Alzheimer’s project and Pfizer’s zavegepant, with an adcom for Cidara’s rezafungin.
Go or no go? Novartis eyes a big new growth driver
The biggest approval decision in October will involve Novartis’s eye asset Beovu, while Biogen and Alkermes face a key verdict in MS.
Japanese biopharma rules mid-cap returns
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
Small and mid-cap share price gains make up for majors
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.
M&A: 2017 proves snooze-worthy on the acquisition front
Pharma and biotech takeover activity slumps to a five-year low in 2017.
